English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, October 16, 2020
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Thursday, October 8, 2020
The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology
Tuesday, October 6, 2020
エーザイ、TLR4拮抗剤エリトランおよび抗FKN 抗体E6011を用いたCOVID-19治療薬の開発を目指す産学官共同研究開発契約を締結し、非臨床研究活動を開始
Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded
Thursday, October 1, 2020
エーザイと生化学工業、変形性関節症治療剤SI-613について韓国における販売提携に関する契約を締結
Wednesday, September 30, 2020
Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea
エーザイ、人事異動ならびに組織改編(2020年10月1日付)を発表
Monday, September 28, 2020
ギリアドとエーザイ、「ジセレカ(R)錠」(一般名:フィルゴチニブマレイン酸塩)について日本で関節リウマチに関する製造販売承認を取得
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis
Wednesday, September 23, 2020
エーザイ、抗てんかん剤「Fycompa(R)」の小児適応に関して欧州医薬品庁の医薬品委員会より承認勧告を受領

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575